Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Dean Follmann"'
Publikováno v:
Statistics in Medicine. 40:4492-4504
Repeated low-dose challenge studies provide valuable information when evaluating candidate vaccines since they resemble the typical exposure of natural transmission and inform on the number of exposures prior to infection. Traditionally, the number o
Autor:
Dominic Esposito, Sandeep Narpala, Emily T. Martin, Allyson Mateja, Sarah O’Connell, Dean Follmann, Adrian B. McDermott, Joshua G. Petrie, Christian Hatcher, Latifa Bazzi, Arnold S. Monto
Publikováno v:
The Journal of Infectious Diseases. 224:49-59
Background We investigated frequency of reinfection with seasonal human coronaviruses (HCoVs) and serum antibody response following infection over 8 years in the Household Influenza Vaccine Evaluation (HIVE) cohort. Methods Households were followed a
Autor:
Michele P. Andrasik, Weiping Deng, Yiwen Lu, Bob C. Lin, Ruben O. Donis, Youyi Fong, Mira Baron, Lindsay N. Carpp, Lars W. P. van der Laan, Immune Assays Team, Adrian B. McDermott, Karen Martins, Lindsey R. Baden, Flora Castellino, James G. Kublin, Luis De La Cruz, Honghong Zhou, Chuong Huynh, Rolando Pajon, Amanda Eaton, David Benkeser, Mark Kutner, Dean Follmann, Marcella Sarzotti-Kelsoe, CoVPN Biostatistics Team, Hana M. El Sahly, Charlene McDanal, Jacqueline Miller, Christopher R. Houchens, Nima S. Hejazi, Kathleen M. Neuzil, Spyros A. Kalams, Bhavesh Borate, Coronavirus Efficacy (Cove) Team, David C. Montefiori, Lakshmi Jayashankar, Colleen F. Kelley, Richard A. Koup, Britta Flach, Peter B. Gilbert, Lawrence Corey, Chenchen Yu
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 4
article-version (status) pre
article-version (number) 4
BackgroundIn the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffccfeae7ead57a33edd54278a0c324
https://doi.org/10.1101/2021.08.09.21261290
https://doi.org/10.1101/2021.08.09.21261290
Autor:
Dean Follmann
Publikováno v:
Wiley StatsRef: Statistics Reference Online. :1-5
Autor:
Dean Follmann, Michel C. Nussenzweig, Malcolm A. Martin, Michael S. Seaman, Natalie Gaughan, Bruce J. Swihart, Yoshiaki Nishimura, Alicia Buckler-White, Till Schoofs, Anna Gazumyan, Rajeev Gautam
Publikováno v:
Nature Medicine. 24:610-616
In the absence of an effective and safe vaccine against HIV-1, the administration of broadly neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus transmission. Here, we introduced two mutations encoding amino aci
Autor:
Dean Follmann, Chiung Yu Huang
Publikováno v:
Biometrics. 74:1023-1033
Assessment of vaccine efficacy as a function of the similarity of the infecting pathogen to the vaccine is an important scientific goal. Characterization of pathogen strains for which vaccine efficacy is low can increase understanding of the vaccine'
Autor:
Dean Follmann
Publikováno v:
Statistical Communications in Infectious Diseases. 11
Effective HIV prevention has the potential to change the landscape of HIV prevention trials. Low infection rates will make superiority studies necessarily large while non-inferiority trials will need some evidence that a counterfactual placebo group
Autor:
Mosoka Fallah, Eric Stavale, Dean Follmann, Greg Grandits, James Pettitt, Kaylie Tuznik, Gene G. Olinger, James Logue, Yeya dit Sadio Sarro, Jonathan Marchand, Cavan S. Reilly, Fatorma K. Bolay, Lisa E. Hensley
Publikováno v:
Journal of virological methods. 255
As part of the scientific community's development of medical countermeasures against Ebola virus disease, optimization of standardized assays for product evaluation is paramount. The recent outbreak heightened awareness to the scarcity of available a
Publikováno v:
Statistics in Medicine. 34:1791-1798
There are many different strains of malaria parasites, each represented by a unique sequence of amino acids. A desirable vaccine would match the amino acid sequence of the parasite antigen. Because of the three-dimensional structure of protein, not a
Autor:
Bennett A. Peterson, Matthew G. Zimmerman, Andy Patamawenu, Stephen A. Migueles, Daniel Mendoza, Claire W. Hallahan, Sushila A. Toulmin, Eric Galson, Kelly M. Martins, Dean Follmann, Elizabeth P. Kelly, Mark Connors, Catherine Rehm, Alexander Ober, Sarah A. Johnson, Kate O. Poropatich, Hiromi Imamichi, Sara Jones
Publikováno v:
EBioMedicine, Vol 2, Iss 1, Pp 46-58 (2015)
EBioMedicine
EBioMedicine
Understanding natural immunologic control over Human Immunodeficiency Virus (HIV)-1 replication, as occurs in rare long-term nonprogressors/elite controllers (LTNP/EC), should inform the design of efficacious HIV vaccines and immunotherapies. Durable